Literature DB >> 12417326

Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells.

Ryuta Yamazaki1, Natsuko Kusunoki, Takeshi Matsuzaki, Shusuke Hashimoto, Shinichi Kawai.   

Abstract

Although the influence of selective cyclooxygenase (COX)-2 inhibitors on the proliferation of colon adenocarcinoma cells have been the subject of much investigation, relatively little research has compared the effects of different COX-2 inhibitors. Celecoxib strongly suppressed the proliferation of COX-2 expressing HT-29 cells at 10-40 microM. NS-398 and nimesulide also inhibited cell proliferation, whereas rofecoxib, meloxicam, and etodolac did not. Only celecoxib induced apoptosis of HT-29 cells, as detected on the basis of DNA fragmentation, TUNEL positivity, and caspase-3/7 activation. DNA fragmentation was also increasd in COX-2 non-expressing cell lines (SW-480 and HCT-116) by exposure to celecoxib for 6-24 h. All six COX-2 inhibitors suppressed the production of prostaglandin E(2) by HT-29 cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to inhibition of COX-2. Inactivation of Akt might explain the differential pro-apoptotic effect of these selective COX-2 inhibitors on colon adenocarcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417326     DOI: 10.1016/s0014-5793(02)03535-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

1.  Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-kappaB and crosstalk between the extrinsic and intrinsic apoptotic pathways.

Authors:  Chiung-Hua Huang; Jih-Hwa Guh; Grace Shiahuy Chen; Pin-Hsuan Lu; Ji-Wang Chern
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-08       Impact factor: 3.000

Review 2.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

Review 3.  The Wnt signaling pathway in cancer.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Crit Rev Oncol Hematol       Date:  2015-12-24       Impact factor: 6.312

Review 4.  Evolving management of colorectal cancer.

Authors:  Jochem van der Voort van Zijp; Harald J Hoekstra; Marc D Basson
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

5.  Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.

Authors:  Jason R Gee; Corrie B Burmeister; Thomas C Havighurst; Kyungmann Kim
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

Review 6.  Pharmacologic Manipulation of Wnt Signaling and Cancer Stem Cells.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Methods Mol Biol       Date:  2017

7.  From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.

Authors:  Bo Zhong; Xiaohan Cai; Snigdha Chennamaneni; Xin Yi; Lili Liu; John J Pink; Afshin Dowlati; Yan Xu; Aimin Zhou; Bin Su
Journal:  Eur J Med Chem       Date:  2011-11-15       Impact factor: 6.514

8.  Chemoprevention of colon cancer in a rat carcinogenesis model using a novel nanotechnology-based combined treatment system.

Authors:  Abhishek Chaudhary; Dhruvitkumar Sutaria; Ying Huang; Jeffrey Wang; Sunil Prabhu
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-13

Review 9.  The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.

Authors:  Mathias Gehrmann; Jürgen Radons; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2008-02-05       Impact factor: 3.667

10.  11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.

Authors:  Shilin Yang; Li Jiang; Ming-Zhi Zhang
Journal:  J Oncobiomarkers       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.